Last reviewed · How we verify
Analogous GanMaoKangNing Granules
Analogous GanMaoKangNing Granules is a Small molecule drug developed by Dalian Zhen-Ao Bio-Tech Co., Ltd.. It is currently in Phase 2 development.
At a glance
| Generic name | Analogous GanMaoKangNing Granules |
|---|---|
| Sponsor | Dalian Zhen-Ao Bio-Tech Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Analogous GanMaoKangNing Granules CI brief — competitive landscape report
- Analogous GanMaoKangNing Granules updates RSS · CI watch RSS
- Dalian Zhen-Ao Bio-Tech Co., Ltd. portfolio CI
Frequently asked questions about Analogous GanMaoKangNing Granules
What is Analogous GanMaoKangNing Granules?
Analogous GanMaoKangNing Granules is a Small molecule drug developed by Dalian Zhen-Ao Bio-Tech Co., Ltd..
Who makes Analogous GanMaoKangNing Granules?
Analogous GanMaoKangNing Granules is developed by Dalian Zhen-Ao Bio-Tech Co., Ltd. (see full Dalian Zhen-Ao Bio-Tech Co., Ltd. pipeline at /company/dalian-zhen-ao-bio-tech-co-ltd).
What development phase is Analogous GanMaoKangNing Granules in?
Analogous GanMaoKangNing Granules is in Phase 2.